About Amyl Therapeutics

A preclinical-stage biotechnology company pioneering a breakthrough approach to treat rare and severe peripheral protein misfolding diseases and neurodegenerative diseases.

Our Science

Our scientists work on a proprietary technology, that is able to bind to various types of amyloid fibrils and induce their clearance.


Our Programmes

Our therapies are designed to target multiple misfolded proteins implicated in both peripheral diseases involving systemic protein misfolding pathologies and neurodegenerative diseases.

Learn more about
Amyl Therapeutics